153 related articles for article (PubMed ID: 2203517)
1. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma.
Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
Cancer; 1990 Sep; 66(5 Suppl):1074-9. PubMed ID: 2203517
[TBL] [Abstract][Full Text] [Related]
2. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
Janknegt RA; Abbou CC; Bartoletti R; Bernstein-Hahn L; Bracken B; Brisset JM; Da Silva FC; Chisholm G; Crawford ED; Debruyne FM
J Urol; 1993 Jan; 149(1):77-82; discussion 83. PubMed ID: 7678043
[TBL] [Abstract][Full Text] [Related]
3. Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review.
Du Plessis DJ
Urology; 1991; 37(2 Suppl):20-4. PubMed ID: 1992599
[TBL] [Abstract][Full Text] [Related]
4. Combination of Anandron with orchiectomy in treatment of metastatic prostate cancer. Results of a double-blind study.
Beland G
Urology; 1991; 37(2 Suppl):25-9. PubMed ID: 1992600
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).
Bertagna C; De Géry A; Hucher M; François JP; Zanirato J
Br J Urol; 1994 Apr; 73(4):396-402. PubMed ID: 8199827
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group.
Dijkman GA; Janknegt RA; De Reijke TM; Debruyne FM
J Urol; 1997 Jul; 158(1):160-3. PubMed ID: 9186345
[TBL] [Abstract][Full Text] [Related]
7. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group.
Janknegt RA
Cancer; 1993 Dec; 72(12 Suppl):3874-7. PubMed ID: 8252507
[TBL] [Abstract][Full Text] [Related]
8. Total androgen ablation: Canadian experience.
Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
Urol Clin North Am; 1991 Feb; 18(1):75-82. PubMed ID: 1992574
[TBL] [Abstract][Full Text] [Related]
9. Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies.
Hucher M; de Gery A; Bertagna C
Cancer; 1993 Dec; 72(12 Suppl):3886-7. PubMed ID: 8252510
[No Abstract] [Full Text] [Related]
10. Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group.
Dijkman GA; Fernandez del Moral P; Debruyne FM; Janknegt RA
Eur Urol; 1995; 27(3):196-201. PubMed ID: 7601182
[TBL] [Abstract][Full Text] [Related]
11. Nilutamide: an antiandrogen for the treatment of prostate cancer.
Dole EJ; Holdsworth MT
Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
[TBL] [Abstract][Full Text] [Related]
12. Total androgen ablation in the treatment of metastatic prostatic cancer. The Canadian Anandron Study Group.
Semin Urol; 1990 Aug; 8(3):159-65. PubMed ID: 2204980
[No Abstract] [Full Text] [Related]
13. Anandron (RU 23908) associated with orchiectomy in stage D prostate cancer. Preliminary results of a randomized, double-blind study.
Namer M; Amiel J; Toubol J
Am J Clin Oncol; 1988; 11 Suppl 2():S191-6. PubMed ID: 3071952
[TBL] [Abstract][Full Text] [Related]
14. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
Decensi AU; Boccardo F; Guarneri D; Positano N; Paoletti MC; Costantini M; Martorana G; Giuliani L
J Urol; 1991 Aug; 146(2):377-81. PubMed ID: 1856935
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study].
Knönagel H; Bolle JF; Hering F; Senn E; Hodel T; Neuenschwander H; Biedermann C
Helv Chir Acta; 1989 Aug; 56(3):343-5. PubMed ID: 2681086
[TBL] [Abstract][Full Text] [Related]
16. Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.
Boccardo F; Decensi AU; Guarneri D; Martorana G; Fioretto L; Mini E; Macaluso MP; Giuliani L; Santi L; Periti P
Cancer Detect Prev; 1991; 15(6):501-3. PubMed ID: 1782640
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer who Underwent Orchiectomy: A Systematic Review and Metaanalysis.
Rashid M; Shamshavali K; Chhabra M
Curr Clin Pharmacol; 2019; 14(2):108-115. PubMed ID: 30648519
[TBL] [Abstract][Full Text] [Related]
18. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
[TBL] [Abstract][Full Text] [Related]
19. Total androgen blockade for metastatic cancer of the prostate.
Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM
Am J Clin Oncol; 1988; 11 Suppl 2():S187-90. PubMed ID: 3149456
[TBL] [Abstract][Full Text] [Related]
20. Nilutamide approved for metastatic prostate cancer.
Am J Health Syst Pharm; 1996 Dec; 53(23):2784. PubMed ID: 8957341
[No Abstract] [Full Text] [Related]
[Next] [New Search]
